Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events.
- DOI
- 10.1002/cam4.71484
- Published
- 2025 Dec
- Container
- Cancer medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cam4.71484,
title = {Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events.},
author = {Obeng-Kusi M and De Nigris E and Leng S and Farooqui MZH and Yapici HO and Weimer I and Jiao W and Hyatt HW and Zhang X and Lodaya K and Dingli D},
year = {2025},
journal = {Cancer medicine},
doi = {10.1002/cam4.71484},
url = {https://doi.org/10.1002/cam4.71484}
}RIS
TY - JOUR TI - Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events. AU - Obeng-Kusi M AU - De Nigris E AU - Leng S AU - Farooqui MZH AU - Yapici HO AU - Weimer I AU - Jiao W AU - Hyatt HW AU - Zhang X AU - Lodaya K AU - Dingli D PY - 2025 JO - Cancer medicine DO - 10.1002/cam4.71484 UR - https://doi.org/10.1002/cam4.71484 ER -
APA
M, O., E, D. N., S, L., MZH, F., HO, Y., I, W., W, J., HW, H., X, Z., K, L., & D, D. (2025). Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events.. Cancer medicine. https://doi.org/10.1002/cam4.71484
Source records
- pubmed · retrieved 2026-09-27T14:56:49.464Z